Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Karyopharm Therapeutics
Karyopharm will conduct another trial of the drug in p53 wild-type endometrial cancer after the FDA said SIENDO data were insufficient for approval.
Karyopharm’s Phase III SIENDO study showed what analysts called a “modest” progression-free survival improvement overall, but a fourfold improvement in patients with wild-type p53.
Out of the more than 40 approvals granted to new drugs in China in 2021, domestic companies bagged around half to catch up with their multinational peers in the annual innovation scorecard.
Ahead of the usual flurry of deal-making in January, Roche gets retinal cell therapy candidate from Lineage Cell Therapeutics, Pfizer subsidiary Amplyx licenses antiviral candidate to Vera, and GSK expands neurology tie-up with Ligand.
- Other Names / Subsidiaries
- NPM Pharma, Inc.